T1	p 233 360	patients with epithelial ovarian carcinoma that recurred after or did n't respond to first-line , platinum-based chemotherapy .
T2	p 382 429	Patients with measurable and assessable disease
T3	p 710 778	A total of 474 patients were treated ( 239 PLD and 235 topotecan ) .
T4	i 79 129	pegylated liposomal doxorubicin versus topotecan .
T5	i 176 215	pegylated liposomal doxorubicin ( PLD )
T6	i 220 229	topotecan
T7	i 331 360	platinum-based chemotherapy .
T8	i 464 467	PLD
T9	i 520 529	topotecan
T10	i 753 756	PLD
T11	i 765 776	topotecan )
T12	i 950 953	PLD
T13	i 958 967	topotecan
T14	i 1068 1071	PLD
T15	i 1091 1102	topotecan .
T16	i 1202 1205	PLD
T17	i 1275 1278	PLD
T18	i 1301 1312	topotecan .
T19	i 1336 1339	PLD
T20	i 1370 1379	topotecan
T21	i 1545 1554	topotecan
T22	i 1618 1627	topotecan
T23	i 1846 1849	PLD
T24	o 153 161	efficacy
T25	o 166 172	safety
T26	o 831 870	overall progression-free survival rates
T27	o 923 945	overall response rates
T28	o 1020 1049	Median overall survival times
T29	o 1210 1235	progression-free survival
T30	o 1317 1333	overall survival
T31	o 1569 1596	Severe hematologic toxicity
T32	o 1695 1739	growth factor or blood product utilization .
T33	o 1766 1774	efficacy
T34	o 1787 1793	safety